⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18845531 | 0.81 | — | — | |
| SCHEMBL1604426 | 0.73 | — | — | |
| SCHEMBL1604420 | 0.73 | — | — | |
| SCHEMBL5825103 | 0.70 | TRPA1 (0.37) | — | |
| SCHEMBL31537744 | 0.69 | SLC7A5 (0.48) | — | |
| SCHEMBL31233875 | 0.67 | — | — | |
| SCHEMBL9735239 | 0.65 | — | — | |
| SCHEMBL1939208 | 0.65 | — | — | |
| SCHEMBL11884057 | 0.65 | — | — | |
| SCHEMBL483875 | 0.64 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8846893-B2 | Non-ionically bound constructs, and compositions and kits comprising domains | ENZO BIOCHEM, INC. (US) | 2014-09-30 | — | — | US | disclosed |
| US-8742090-B2 | Property effecting and/or property exhibiting compositions for therapeutic and diagnostic uses | ENZO BIOCHEM, INC. (US) | 2014-06-03 | — | — | US | disclosed |
| US-8735145-B2 | Property effecting and/or property exhibiting compositions for therapeutic and diagnostic uses | ENZO BIOCHEM, INC. (US) | 2014-05-27 | — | — | US | disclosed |
| EP-2042606-A1 | Novel property effecting and/or property exhibiting compositions for therapeutic and diagnostic use | ENZO THERAPEUTICS, INC. (US) | 2009-04-01 | — | — | EP | disclosed |
| US-20080248564-A1 | Expression vector comprising ligand conjugates for use and expression of heterologus nucleotide sequences in cells | ENZO THERAPEUTICS, INC. (US) | 2008-10-09 | — | — | US | disclosed |
| EP-0779365-B1 | Methods to introduce nucleic acid into cells for therapeutic and diagnostic uses | ENZO THERAPEUTICS INC (US) | 2008-09-17 | — | — | EP | disclosed |
| US-20080108139-A1 | Expression vector comprising nucleotide sequences coding polymerase for use in eukaryotic specific expression of functional heterologous proteins | ENZO THERAPEUTICS, INC. (US) | 2008-05-08 | — | — | US | disclosed |
| US-20030104620-A1 | Expression vector for expression of heterologous polypeptides and amplification of cell viral resistance; viricides | ENZO BIOCHEM, INC. | 2003-06-05 | — | — | US | disclosed |
| US-20030087434-A1 | Expression vector for use gene transfer tool in genetic engineering | ENZO BIOCHEM, INC. | 2003-05-08 | — | — | US | disclosed |
| US-20010007767-A1 | Genetic engineering | ENZO BIOCHEM, INC. | 2001-07-12 | — | — | US | disclosed |
| US-20010006815-A1 | Chemical modification | ENZO BIOCHEM, INC. | 2001-07-05 | — | — | US | disclosed |
| US-20010006814-A1 | Chemical modification | ENZO BIOCHEM, INC. | 2001-07-05 | — | — | US | disclosed |
| US-20010006816-A1 | Dna, rna hybrid | ENZO BIOCHEM, INC. | 2001-07-05 | — | — | US | disclosed |
| EP-0779365-A2 | Methods to introduce nucleic acid into cells for therapeutic and diagnostic uses | ENZO THERAPEUTICS, INC. (US) | 1997-06-18 | — | — | EP | disclosed |